Financial Architects (New Jersey)’s Larimar Therapeutics LRMR Stock Holding History

Financial Architects (New Jersey)’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-133	Closed	-$7K	–	1507
2017 Q4	$7K	Hold	133	–	–	﹤0.01%	1230
2017 Q3	$6K	Hold	133	–	–	﹤0.01%	1243
2017 Q2	$6K	Hold	133	–	–	﹤0.01%	1241
2017 Q1	$7K	Hold	133	–	–	﹤0.01%	1217
2016 Q4	$5K	Hold	133	–	–	﹤0.01%	1153
2016 Q3	$5K	Hold	133	–	–	﹤0.01%	1148
2016 Q2	$10K	Buy	+133	New	+$10.5K	﹤0.01%	975

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Financial Architects (New Jersey)'s LRMR Position: Q1 2018 in Review

Financial Architects (New Jersey) sold out of Larimar Therapeutics (LRMR) in Q1 2018, closing a stake of 133 shares — an estimated $7K sold.

Financial Architects (New Jersey) first reported a position in LRMR in Q2 2016 and held it in 7 quarters. The position peaked at $10K in Q2 2016. 61 funds tracked by Wall St. Rank hold LRMR as of Q1 2018.

Financial Architects (New Jersey) reported no remaining Larimar Therapeutics position as of Q1 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 133 Larimar Therapeutics shares in Q1 2018, an estimated $7K.
Financial Architects (New Jersey) first reported a position in Larimar Therapeutics in Q2 2016 and held it in 7 quarters.
Financial Architects (New Jersey)'s Larimar Therapeutics position peaked at $10K in Q2 2016.
61 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2018, filed 23 Apr 2018.